Luis G Paz-Ares MD PhD discdusses the addition of lurbinectedin as maintenance therapy for extensive stage small cell lung cancer (SCLC)
Audio Journal of Oncology
An interview with:
Luis G Paz-Ares MD PhD, Chair of Medical Oncology, Hospital Universitario 12 de Octubre, Universitario de Madrid
Comment by:
Julie R. Gralow MD FACP FASCO, Chief Medical Officer and Executive Vice President, American Society of Clinical Oncology.
https://www.audiomedica.com/wp-content/2025/06/Luis-Paz-Ares-PRODUCTION-MASTER-.mp3CHICAGO, USA—Patients with extensive stage small cell lung cancer had longer disease-free survival and lived longer when the drug lurbinectedin (a DNA damaging agent) was added to their maintenance therapy after induction using standard immunochemotherapy. At the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO) the Audio Journal of Oncology heard from lead-author of the phase three IMforte study, Luis G Paz-Ares MD PhD from the University Hospital of the 12th of October in Madrid Spain and from Julie R. Gralow MD FACP FASCO, Chief Medical Officer and Executive Vice President of ASCO.
Podcast Script:
SARAH MAXWELL:
Hello and welcome to the Audio Journal of Oncology. I’m Sarah Maxwell. We’re reporting from the 2025 Annual Meeting of the American Society of Clinical Oncology held in Chicago.
There was encouraging news from the phase-three IMforte trial in patients with small cell lung cancer. The addition of a new DNA damaging agent – lurbinectedin – seems to be adding statistically significant and clinically meaningful extensions of progression-free and overall survival.
First Author Luis Paz-Ares, who chairs the Medical Oncology Department at the University of the 12th of October in Madrid, has been telling Peter Goodwin about the study findings:
INTERVIEW: Paz Ares/Goodwin
SARAH MAXWELL:
To get a comment on what Dr. Paz-Ares had to say, Peter attended an ASCO press briefing about the IMforte trial. It was chaired by ASCO’s Chief Medical Officer and Executive Vice President: Julie Gralow, who gave her reactions:
COMMENT: Julie Gralow MD FACP FASCO
Julie Gralow of the American Society of Clinical Oncology, adding her thoughts to what Luis Paz-Ares told us about the IMforte trial results in patients with small-cell lung cancer. And that’s all from this edition of the Audio Journal of Oncology. From me, Sarah Maxwell, goodbye.
ASCO ABSTRACT TITLE
“Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial.”
https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.8006
https://www.audiomedica.com/wp-content/2025/06/Luis-Paz-Ares-PRODUCTION-MASTER-1-1.mp3
Tags
Related Episodes
Martin Wermke MD; ESMO 2025: Initial Therapy with Bi-Specific T-cell Engager Tarlatamab Promises Better Outcomes in Patients with Small Cell Lung Cancer
Tarlatamab, a bi-specific T-cell engager drug added to innitial immunochemotherapy brought encouraging initial survival outcomes in the DeLLphi-303 reported at the European Society for Medical Oncolog
Javier C Cortés MD PhD: ESMO 2025, Berlin: Initial Therapy with Sacituzumab Govitecan Improves Progression-Free Survival in Patients with Newly-Diagnosed Metastatic Triple Negative Breast Cancer—ASCENT-03 study
Javier Cortés tells his findings from ASCENT-03 as reported to ESMO 2025 in Berlin with antibody drug conjugate as initial therapy for TNBC in patients testing negative for PD-1/PD-L1
Rebecca Dent MD: ESMO Previous Highlights: Neo-Adjuvant Therapy for Triple Negative Breast Cancer, Checkpoint Inhibition, AI, Cancer Vaccines, and More ……
Rebecca Dent surveys the most recent ESMO Annual Meeting to prepare our thoughts for the ESMO 2025 meeting